Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:RYTM News 11 December 2025 - 30 December 2025

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

NEW YORK, December 30, 2025, 13:33 ET — Regular session Rhythm Pharmaceuticals shares were down 4.2% at $107.85 at 1:33 p.m. ET on Tuesday, after trading as low as $106.65. The move matters because Rhythm is a single-product rare-disease biotech whose stock has tended to swing on regulatory and clinical milestones for Imcivree, its obesity drug. Investors are watching the company’s next U.S. Food and Drug Administration decision closely. With the next major catalyst still ahead, the stock can move sharply on broader risk sentiment in biotech, even when there is no fresh company news. The SPDR S&P Biotech ETF
30 December 2025
····
Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals (RYTM) Hits Record High on Rare-Disease Breakthrough: Latest News, Stock Forecast and Analyst Outlook

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) stock is on a tear. On 11 December 2025, shares surged to a new all‑time high after the company reported encouraging mid‑stage data in Prader‑Willi syndrome (PWS) and investors refocused on a growing obesity franchise built around its melanocortin‑4 receptor (MC4R) agonist, IMCIVREE (setmelanotide).Investing.com+1 As of Thursday morning, RYTM was trading around $121 per share, up more than 15% on the day according to real‑time data from MarketBeat, and roughly 80–90% higher year‑to‑date.MarketBeat+2Investing.com+2 For a mid‑cap biotech that is still loss‑making, that kind of move demands a closer look at what changed, what analysts expect
11 December 2025
····

Stock Market Today

Blockchain’s New Pitch: Tracking Supply-Chain Emissions for a Price

Blockchain’s New Pitch: Tracking Supply-Chain Emissions for a Price

7 February 2026
Blockchain industry groups are promoting supply-chain emissions tracking and data transparency, not crypto trading, as key business uses. Companies face mounting pressure to map Scope 3 emissions, which are often hard to verify. Past blockchain supply-chain projects, including Maersk’s TradeLens, struggled with adoption when partners failed to participate.
Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

Ashtead share price in focus as buyback rolls on and NYSE switch clocks closer

7 February 2026
Ashtead shares closed Friday at 4,936p, up 1.09%, after the company bought 88,872 shares under its repurchase program. The group is set to shift its primary listing to New York on March 2, pending court approval, and will be removed from the FTSE UK index the same day. Ashtead paid a half-year dividend of 37.5 U.S. cents per share on Friday.
Go toTop